2023

DNA repair and therapeutic stratagies in cancer stem cells. Gillespie MS, Ward CM and Davies CC. Cancers 15 (6) 1897. doi: 10.3390/cancers15061897 

​​

2021

Arginine methylation and ubquitylation crosstalk controls DNA end-resection and homologous recombination repair. Sanchez-Bailon MP, Choi S-Y, Dufficy ER, Sharma K, McNee GS, Gunnell EA,  Chiang K, Sahay D, Maslem S, Stewart GS, Skehel JM, Dreveny I. Davies CC. Nature Communications   12 (1):4):6313.  doi:10.1038/s41467-021-26413-6.PMID: 34728620 

​

2020

Structural and Biochemical Evaluation of Bisubstrate Inhibitors of Protein Arginine N-methyltransferases PRMT1 and CARM1 (PRMT4). Gunnell EA, Al-Noori A, Muhsen U, Davies CC, Dowden J, Dreveny I. Biochem Journal   28;477(4):787-800.  doi: 10.1042/BCJ20190826.

​

2019

PRMTs and Arginine Methylation: Cancer's Best-Kept Secret? Jarrold J, Davies CC. Trends Mol Med. 25(11):993-1009. doi: 10.1016/j.molmed.2019.05.007.

​

2018

Linking PRMT5 to breast cancer stem cells: New therapeutic opportunities? Chiang K and Davies CC. Mol Cell Oncol 5 (3):e1441628

​

Protein methylation and the DNA damage response” by Martin R. Higgs and Clare Davies in “DNA Repair and Replication: Mechanisms and Clinical significance”. ASIN: B07H376GWT, published by Garland Science.

 

2017

PRMT5 is a critical regulator of breast cancer stem cells via histone methylation and FOXP1 expression. Chiang K, Zielinska AE, Shaaban AM, Sanchez-Bailon MP, Jarrold J, Clarke TL, Zhang J, Francis A, Jones LJ, Smith S, Barbash O, Guccione E, Farnie G, Smalley MJ, Davies CC . Cell Reports 21(12):3498-3513.

​

PRMT5-dependent methylation of the TIP60 coactivator RUVBL1 is a key regulator of homologous recombination. Clarke TL, Sanchez-Bailon MP, Chiang K, Reynolds JJ, Herrero-Ruiz J, Bandeiras TM, Matias PM, Maslen SL, Skehel JM, Stewart GS, Davies CC.  Molecular Cell 65(5):900-916.e7.

​

Citruillination of Histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma. McNee G, Eales KL, Wei W, Williams DS, Barkhuizen A, Bartlett DB, Essex S, Anandram S, Filer A, Moss PA, Pratt G, Basu S, Davies CC, Tennant DA. Leukemia 31(2):373-381

​

2016

Identifying novel protein interactions: Proteomic methods, optimisation approaches and data analysis pipelines. Carneiro DG, Clarke T, Davies CC, Bailey D. Methods 15;95:46-54. doi:10.1016/j.ymeth.2015.08.022.

​

2015

The extracellular-regulated protein kinase 5 (ERK5) is a key regulator of inflammation-driven cancer. Finegan KG, Perez-Madrigal D, Hitchin JR, Davies CC, Jordan AM, Tournier C. Cancer Research (75): 742-753.

​

​2014

Conditional deletion of mkk4 and mkk7 cooperates with KrasG12D expression to accelerate pancreatic ductal adenocarcinoma in mice. Davies CC, Harvey E, McMahon R, Finegan KG, Connor F, Davies RJ, Tuveson DA, Tournier C. Cancer Research 74 (12), 3344-56.
 
​2013

Arginine methylation: Making its mark on AP-1 gene activation. Davies CC and Behrens A. Cell Cycle 12:15, 2333–2334.  
 
Arginine methylation of the c-Jun co-activator RACO-1 is required for c-Jun/AP-1 activation. Davies CC, Chakraborty A, Diefenbacher ME, Skehel M, and Behrens A. The EMBO Journal  (32) 1556 – 1567.

​

​2012

Exploring the function of the JNK (c-Jun N-terminal kinase) signalling pathway in physiological processes to design novel therapeutic stratagies. Davies C and Tournier C. Biochem Soc Trans. (40):85-9. 
 

​2011

The death domain kinase RIP1 links the immunoregultory CD40 receptor to apoptotic signalling in carcinomas. Knox PG*, Davies CC*, Ioannou M, Eliopoulos AG. J. Cell Biol. Feb 7;192(3):391 *Joint first author

​2010

RACO-1 links AP-1 activity to growth factor signalling. Davies CC, Chakraborty A, Cipriani F, Haigh K, Haigh JJ and Behrens A . Nature Cell Biology (10): 963-72

 

​2005

TRAF6 is required for TRAF2 dependent CD40 signal transduction in non-hemopoietic cells. Davies CC, Mak TW, Young LS, Eliopoulos AG. Mol. Cell Biol.  (25): 9806-19

 

NF-kB overrides the apoptotic program of TNF receptor 1 but not CD40 in carcinoma cells.  Davies CC, Bem D, Young LS, Eliopoulos AG. Cell Signal  (17):  723-38

 

Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. Hill SC, Youde SJ, Man S, Teale GR, Baxendale AJ, Hislop A, Davies CC, Luesley DM, Blom AM, Rickinson AB, Young LS, Eliopoulos AG.  J Immunol (174) 41-50.

 

​2004

Inhibition of PI3K and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells. Davies CC, Mason J, Wakelam MJ, Young LS, Eliopoulos AG.  J Biol Chem. (279): 1010-19

 

​2003

TRAF1 is a critical regulator of JNK signaling by the TRAF-binding domain of the Epstein-Barr virus-encoded latent infection membrane protein 1 but not CD40. Eliopoulos AG, Waites ER, Blake SM, Davies C, Murray P, Young LS . J Virol. (77):1316-28.

​

​2002

The oncogenic protein kinase Tpl-2/Cot contributes to Epstein-Barr virus-encoded latent infection membrane protein 1-induced NF-kappaB signaling downstream of TRAF2. Eliopoulos AG, Davies C, Blake SS, Murray P, Najafipour S, Tsichlis PN, Young LS . J Virol. (76):4567-79.

 

​2000 

CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily.  Eliopoulos AG, Davies C, Knox PG, Gallagher NJ, Afford SC, Adams DH, Young LS.  Mol Cell Biol.  (20):5503-15.

 

​